Company news
GC Biopharma Corp. news in 2025
GC Biopharma Corp.'s news releases, calls and decks from 2025, newest first.
GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
December 22, 2025
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
December 8, 2025
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
December 1, 2025
GC Biopharma Supports New Insights into Education, Safety, and Patient Outcomes in Ig Therapy Care at the 2025 IgNS Annual Meeting
November 6, 2025
GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity in Phase 2 Data, Published in 'Vaccine'
November 3, 2025
GC Biopharma Announces Symposium on Clinical and Patient Experience in Primary Immunodeficiency and Poster Presentations on IVIG Manufacturing and Viscosity at the 2025 IgNS Annual Meeting
October 15, 2025
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
October 13, 2025
GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
September 22, 2025
GC Biopharma submits IND to begin Phase 3 Clinical Trial for BARYCELA in Thailand
August 28, 2025
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
August 21, 2025
GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
August 18, 2025
GC Biopharma Announces Publication Demonstrating 14-Day Stability of Pooled ALYGLO® Under Refrigerated Conditions
August 11, 2025
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
July 17, 2025
GC Biopharma Presents New Viscosity Research on IVIG Products at ISTH 2025
July 16, 2025
GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
May 30, 2025
GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California
May 14, 2025
GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine
April 8, 2025